Daily nursing for multiple myeloma: whole life cycle health management based on the doctor-nurse-patient integration model_West China Medical Journal

Authors：

SHEN Hongyu , TANG Wenjiao , CHEN Fengjiao , LENG Yamei ,  ZHANG Li , PAN Ling , NIU Ting

Department of Hematology, West China Hospital, Sichuan University / West China School of Nursing, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding?author：

ZHANG Li, Email: drzhangli2014@sina.com

Keywords：

Multiple myeloma; doctor-nurse-patient integration; whole life cycle health management; nursing

DOI：

10.7507/1002-0179.202310136

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

With the continuous development of new drugs and immunotherapy, the survival period of patient with multiple myeloma (MM) is continuously prolonged, and the disease is becoming chronic. Due to the involvement of multiple systems and numerous complications, the daily nursing for MM faces significant challenges. The doctor-nurse-patient integration model and the whole life cycle health management model for daily nursing of MM are expected to reduce the social burden related to diseases, improve patients’ quality of life, and reduce medical costs. This article provides a review on three aspects of MM doctor-nurse-patient integration, whole life cycle health management, and daily health management involving multiple systems.

Citation： SHEN Hongyu, TANG Wenjiao, CHEN Fengjiao, LENG Yamei, ZHANG Li, PAN Ling, NIU Ting. Daily nursing for multiple myeloma: whole life cycle health management based on the doctor-nurse-patient integration model. West China Medical Journal, 2025, 40(3): 490-494. doi: 10.7507/1002-0179.202310136 Copy

1.	Wang S, Xu L, Feng J, et al. Prevalence and Incidence of multiple myeloma in urban area in China: a national population-based analysis. Front Oncol, 2020, 9: 1513.
2.	Liu W, Liu J, Song Y, et al. Mortality of lymphoma and myeloma in China, 2004-2017: an observational study. J Hematol Oncol, 2019, 12(1): 22.
3.	陳雅姝, 劉敏, 徐曉旭, 等. 多發性骨髓瘤患者存活期的危險因素分析. 解放軍預防醫學雜志, 2019, 37(7): 78-79.
4.	唐榮芳, 董敏, 伍志梅, 等. 老年多發性骨髓瘤化療病人醫院感染特點及影響因素分析. 實用老年醫學, 2020, 34(2): 125-129.
5.	Gay F, Engelhardt M, Terpos E, et al. From transplant to novel cellular therapies in multiple myeloma: European myeloma network guidelines and future perspectives. Haematologica, 2018, 103(2): 197-211.
6.	American Nurses Association. Nersing’s social policy statement. Washington DC: American Nurse’s Publishing, 1995: 104-108.
7.	沈曉, 張培慶, 李文霞, 等. 醫護一體化護理對糖尿病住院患者血糖控制及遵醫行為的影響. 國際護理學雜志, 2018, 37(7): 911-914.
8.	繆成君, 吳艷. 醫護一體化健康教育對肺結核患者疾病認知水平及自我管理能力的影響. 醫學臨床研究, 2019, 36(12): 2490-2492.
9.	李一桔, 陳云霞, 陸萍, 等. 醫護一體化模式對乳腺癌患者改良根治術后上肢功能訓練自我效能及康復效果的影響. 醫學臨床研究, 2021, 38(3): 455-457.
10.	李德勤, 張瑾, 曹竹如, 等. 病房-門診-家庭醫護一體化管理對慢性腎臟病患者負性情緒和自我護理能力的影響. 安徽醫學, 2021, 42(11): 1302-1305.
11.	國家衛生和計劃生育委員會, 李斌. 《“健康中國 2030”規劃綱要》輔導讀本. 北京: 人民衛生出版社, 2017: 11-12.
12.	劉潔, 魏力. 全周期疾病管理對多發性骨髓瘤患者自我護理能力及并發癥的影響. 天津護理, 2021, 29(2): 138-141.
13.	張艷, 楊敏. 基于醫護一體化的延續性護理模式應用于多發性骨髓瘤患者的效果分析. 中西醫結合護理(中英文), 2021, 7(2): 17-20.
14.	李玉軍, 劉麗洋, 肖娟娟. 新診斷老年多發性骨髓瘤的預后分層及治療進展. 實用腫瘤學雜志, 2022, 36(1): 84-88.
15.	Norful AA, de Jacq K, Carlino R, et al. Nurse practitioner-physician comanagement: a theoretical model to alleviate primary care strain. Ann Fam Med, 2018, 16(3): 250-256.
16.	段嘉宇, 崔健, 唐文嬌, 等. 多發性骨髓瘤疾病全周期健康管理. 中國醫學科學院學報, 2022, 44(4): 673-677.
17.	Ma L, Xu S, Qu J, et al. Monoclonal gammopathy of undetermined significance in Chinese population: a prospective epidemiological study. Hematol Oncol, 2019, 37(1): 75-79.
18.	魏宇君, 黃仲夏. 多發性骨髓瘤病情演變和早期診斷研究進展. 腫瘤學雜志, 2020, 26(2): 81-85.
19.	Michels TC, Petersen KE. Multiple myeloma: diagnosis and treatment. Am Fam Physician, 2017, 95(6): 373-383.
20.	Langseth ?O, Myklebust T?, Johannesen TB, et al. Incidence and survival of multiple myeloma: a population-based study of 10 524 patients diagnosed 1982-2017. Br J Haematol, 2020, 191(3): 418-425.
21.	Brigle K, Rogers B. Pathobiology and diagnosis of multiple myeloma. Semin Oncol Nurs, 2017, 33(3): 225-236.
22.	吳菲, 單鵬, 賀學姣, 等. 15 例多發性骨髓瘤早期誤診臨床探究及啟示. 現代生物醫學進展, 2020, 20(12): 2375-2379.
23.	Joseph NS, Kaufman JL, Dhodapkar MV, et al. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol, 2020, 38(17): 1928-1937.
24.	Binder M, Rajkumar SV, Ketterling RP, et al. Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma. Blood Cancer J, 2016, 6(3): e401.
25.	樊代明. 中國腫瘤整合診治指南(CACA). 天津: 天津科學技術出版, 2022: 1926.
26.	Robak P, Drozdz I, Szemraj J, et al. Drug resistance in multiple myeloma. Cancer Treat Rev, 2018, 70: 199-208.
27.	Holstein SA, Jung SH, Richardson PG, et al. Updated analysis of CALGB (alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol, 2017, 4(9): e431-e442.
28.	Landgren O, Kazandjian D. Modern myeloma therapy + sustained minimal residual disease-negative = (functional) cure!. J Clin Oncol, 2022, 40(25): 2863-2866.
29.	Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2017, 28(suppl 4): iv52-iv61.
30.	中國醫師協會血液科醫師分會, 中華醫學會血液學分會. 中國多發性骨髓瘤診治指南(2022 年修訂). 中華內科雜志, 2022, 61(5): 480-487.
31.	閆宇辰, 李振宇. 復發難治性多發性骨髓瘤的臨床研究進展. 徐州醫科大學學報, 2022, 42(2): 148-151.
32.	郝牧, 邱錄貴. 多發性骨髓瘤腫瘤生物學研究進展. 中國細胞生物學學報, 2022, 44(1): 111-119.
33.	中國臨床腫瘤學會(CSCO)指南工作委員會. 多發性骨髓瘤骨病臨床診療專家共識(2021). 臨床腫瘤學雜志, 2022, 27(1): 65-72.
34.	李高, 張啟科, 魏小芳, 等. 多發性骨髓瘤患者使用硼替佐米化療期間發生肺部感染的臨床危險因素分析. 中國實驗血液學雜志, 2021, 29(1): 152-157.
35.	Zahid MF, Ali N, Nasir M, et al. Infections in patients with multiple myeloma treated with conventional chemotherapy: a single-center, 10-year experience in Pakistan. Hematol Transfus Cell Ther, 2019, 41(4): 292-297.
36.	Chen YK, Han SM, Yang Y, et al. Early mortality in multiple myeloma: experiences from a single institution. Hematology, 2016, 21(7): 392-398.
37.	Khan R, Apewokin S, Grazziutti M, et al. Renal insufficiency retains adverse prognostic implications despite renal function improvement following total therapy for newly diagnosed multiple myeloma. Leukemia, 2015, 29(5): 1195-201.
38.	Bozic B, Rutner J, Zheng C, et al. Advances in the treatment of relapsed and refractory multiple myeloma in patients with renal insufficiency: novel agents, immunotherapies and beyond. Cancers (Basel), 2021, 13(20): 5036.
39.	Mohyuddin GR, Koehn K, Shune L, et al. Renal insufficiency in multiple myeloma: a systematic review and meta-analysis of all randomized trials from 2005-2019. Leuk Lymphoma, 2021, 62(6): 1386-1395.
40.	Mikhael J, Singh E, Rice MS. Real-world renal function among patients with multiple myeloma in the United States. Blood Cancer J, 2021, 11(5): 99.
41.	Faiman B. Diarrhea in multiple myeloma: a review of the literature. Clin J Oncol Nurs, 2016, 20(4): E100-E105.
42.	Hu X, Wang W, Wang Y, et al. Fear of cancer recurrence in patients with multiple myeloma: prevalence and predictors based on a family model analysis. Psychooncology, 2021, 30(2): 176-184.
43.	周鵬飛, 張瑾慧. 心理護理干預對多發性骨髓瘤患者疼痛及生活質量的影響. 中國腫瘤臨床與康復, 2021, 28(10): 1259-1261.
44.	高佳, 孫葉飛. 癌癥患者家庭照顧者復發恐懼的研究進展. 中華護理雜志, 2022, 57(7): 887-891.
45.	楊梅. 護理干預對多發性骨髓瘤患者疼痛、生活質量及心理評分的影響. 現代中西醫結合雜志, 2021, 30(3): 320-323.

1. Wang S, Xu L, Feng J, et al. Prevalence and Incidence of multiple myeloma in urban area in China: a national population-based analysis. Front Oncol, 2020, 9: 1513.
2. Liu W, Liu J, Song Y, et al. Mortality of lymphoma and myeloma in China, 2004-2017: an observational study. J Hematol Oncol, 2019, 12(1): 22.
3. 陳雅姝, 劉敏, 徐曉旭, 等. 多發性骨髓瘤患者存活期的危險因素分析. 解放軍預防醫學雜志, 2019, 37(7): 78-79.
4. 唐榮芳, 董敏, 伍志梅, 等. 老年多發性骨髓瘤化療病人醫院感染特點及影響因素分析. 實用老年醫學, 2020, 34(2): 125-129.
5. Gay F, Engelhardt M, Terpos E, et al. From transplant to novel cellular therapies in multiple myeloma: European myeloma network guidelines and future perspectives. Haematologica, 2018, 103(2): 197-211.
6. American Nurses Association. Nersing’s social policy statement. Washington DC: American Nurse’s Publishing, 1995: 104-108.
7. 沈曉, 張培慶, 李文霞, 等. 醫護一體化護理對糖尿病住院患者血糖控制及遵醫行為的影響. 國際護理學雜志, 2018, 37(7): 911-914.
8. 繆成君, 吳艷. 醫護一體化健康教育對肺結核患者疾病認知水平及自我管理能力的影響. 醫學臨床研究, 2019, 36(12): 2490-2492.
9. 李一桔, 陳云霞, 陸萍, 等. 醫護一體化模式對乳腺癌患者改良根治術后上肢功能訓練自我效能及康復效果的影響. 醫學臨床研究, 2021, 38(3): 455-457.
10. 李德勤, 張瑾, 曹竹如, 等. 病房-門診-家庭醫護一體化管理對慢性腎臟病患者負性情緒和自我護理能力的影響. 安徽醫學, 2021, 42(11): 1302-1305.
11. 國家衛生和計劃生育委員會, 李斌. 《“健康中國 2030”規劃綱要》輔導讀本. 北京: 人民衛生出版社, 2017: 11-12.
12. 劉潔, 魏力. 全周期疾病管理對多發性骨髓瘤患者自我護理能力及并發癥的影響. 天津護理, 2021, 29(2): 138-141.
13. 張艷, 楊敏. 基于醫護一體化的延續性護理模式應用于多發性骨髓瘤患者的效果分析. 中西醫結合護理(中英文), 2021, 7(2): 17-20.
14. 李玉軍, 劉麗洋, 肖娟娟. 新診斷老年多發性骨髓瘤的預后分層及治療進展. 實用腫瘤學雜志, 2022, 36(1): 84-88.
15. Norful AA, de Jacq K, Carlino R, et al. Nurse practitioner-physician comanagement: a theoretical model to alleviate primary care strain. Ann Fam Med, 2018, 16(3): 250-256.
16. 段嘉宇, 崔健, 唐文嬌, 等. 多發性骨髓瘤疾病全周期健康管理. 中國醫學科學院學報, 2022, 44(4): 673-677.
17. Ma L, Xu S, Qu J, et al. Monoclonal gammopathy of undetermined significance in Chinese population: a prospective epidemiological study. Hematol Oncol, 2019, 37(1): 75-79.
18. 魏宇君, 黃仲夏. 多發性骨髓瘤病情演變和早期診斷研究進展. 腫瘤學雜志, 2020, 26(2): 81-85.
19. Michels TC, Petersen KE. Multiple myeloma: diagnosis and treatment. Am Fam Physician, 2017, 95(6): 373-383.
20. Langseth ?O, Myklebust T?, Johannesen TB, et al. Incidence and survival of multiple myeloma: a population-based study of 10 524 patients diagnosed 1982-2017. Br J Haematol, 2020, 191(3): 418-425.
21. Brigle K, Rogers B. Pathobiology and diagnosis of multiple myeloma. Semin Oncol Nurs, 2017, 33(3): 225-236.
22. 吳菲, 單鵬, 賀學姣, 等. 15 例多發性骨髓瘤早期誤診臨床探究及啟示. 現代生物醫學進展, 2020, 20(12): 2375-2379.
23. Joseph NS, Kaufman JL, Dhodapkar MV, et al. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol, 2020, 38(17): 1928-1937.
24. Binder M, Rajkumar SV, Ketterling RP, et al. Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma. Blood Cancer J, 2016, 6(3): e401.
25. 樊代明. 中國腫瘤整合診治指南(CACA). 天津: 天津科學技術出版, 2022: 1926.
26. Robak P, Drozdz I, Szemraj J, et al. Drug resistance in multiple myeloma. Cancer Treat Rev, 2018, 70: 199-208.
27. Holstein SA, Jung SH, Richardson PG, et al. Updated analysis of CALGB (alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol, 2017, 4(9): e431-e442.
28. Landgren O, Kazandjian D. Modern myeloma therapy + sustained minimal residual disease-negative = (functional) cure!. J Clin Oncol, 2022, 40(25): 2863-2866.
29. Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2017, 28(suppl 4): iv52-iv61.
30. 中國醫師協會血液科醫師分會, 中華醫學會血液學分會. 中國多發性骨髓瘤診治指南(2022 年修訂). 中華內科雜志, 2022, 61(5): 480-487.
31. 閆宇辰, 李振宇. 復發難治性多發性骨髓瘤的臨床研究進展. 徐州醫科大學學報, 2022, 42(2): 148-151.
32. 郝牧, 邱錄貴. 多發性骨髓瘤腫瘤生物學研究進展. 中國細胞生物學學報, 2022, 44(1): 111-119.
33. 中國臨床腫瘤學會(CSCO)指南工作委員會. 多發性骨髓瘤骨病臨床診療專家共識(2021). 臨床腫瘤學雜志, 2022, 27(1): 65-72.
34. 李高, 張啟科, 魏小芳, 等. 多發性骨髓瘤患者使用硼替佐米化療期間發生肺部感染的臨床危險因素分析. 中國實驗血液學雜志, 2021, 29(1): 152-157.
35. Zahid MF, Ali N, Nasir M, et al. Infections in patients with multiple myeloma treated with conventional chemotherapy: a single-center, 10-year experience in Pakistan. Hematol Transfus Cell Ther, 2019, 41(4): 292-297.
36. Chen YK, Han SM, Yang Y, et al. Early mortality in multiple myeloma: experiences from a single institution. Hematology, 2016, 21(7): 392-398.
37. Khan R, Apewokin S, Grazziutti M, et al. Renal insufficiency retains adverse prognostic implications despite renal function improvement following total therapy for newly diagnosed multiple myeloma. Leukemia, 2015, 29(5): 1195-201.
38. Bozic B, Rutner J, Zheng C, et al. Advances in the treatment of relapsed and refractory multiple myeloma in patients with renal insufficiency: novel agents, immunotherapies and beyond. Cancers (Basel), 2021, 13(20): 5036.
39. Mohyuddin GR, Koehn K, Shune L, et al. Renal insufficiency in multiple myeloma: a systematic review and meta-analysis of all randomized trials from 2005-2019. Leuk Lymphoma, 2021, 62(6): 1386-1395.
40. Mikhael J, Singh E, Rice MS. Real-world renal function among patients with multiple myeloma in the United States. Blood Cancer J, 2021, 11(5): 99.
41. Faiman B. Diarrhea in multiple myeloma: a review of the literature. Clin J Oncol Nurs, 2016, 20(4): E100-E105.
42. Hu X, Wang W, Wang Y, et al. Fear of cancer recurrence in patients with multiple myeloma: prevalence and predictors based on a family model analysis. Psychooncology, 2021, 30(2): 176-184.
43. 周鵬飛, 張瑾慧. 心理護理干預對多發性骨髓瘤患者疼痛及生活質量的影響. 中國腫瘤臨床與康復, 2021, 28(10): 1259-1261.
44. 高佳, 孫葉飛. 癌癥患者家庭照顧者復發恐懼的研究進展. 中華護理雜志, 2022, 57(7): 887-891.
45. 楊梅. 護理干預對多發性骨髓瘤患者疼痛、生活質量及心理評分的影響. 現代中西醫結合雜志, 2021, 30(3): 320-323.

Previous Article
Application of artificial intelligence in deep brain stimulation therapy
Next Article
Impact of large language model ChatGPT on medical research

West China Medical Journal

Daily nursing for multiple myeloma: whole life cycle health management based on the doctor-nurse-patient integration model

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content